ANXA4 biology may be a potential target for therapeutic intervention [3, 15–21], such as the Annexin A4-NF-κB feedback circuit that activates malignant cell behaviour and tumour growth in gallbladder cancer [18] and Annexin A4 fucosylation that enhances the interaction of ANXA4 with NF-kB p50 and promotes tumour progression in ovarian clear cell carcinoma [17]; toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells [21]. Here, NFKB1 is linked to neoplasm.